BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND MTCP1, C6_1B, 4515, ENSG00000214827, GS1-273L24_4 AND Clinical Outcome
476 results:

  • 1. COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma.
    Liu J; Han D; Xuan J; Xie J; Wang W; Zhou Q; Chen K
    Aging (Albany NY); 2024 Mar; 16(6):5264-5287. PubMed ID: 38466642
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
    Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
    Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification and validation of methylation-CpG prognostic signature for prognosis of hepatocellular carcinoma.
    He C; Guo Z; Zhang H; Yang G; Gao J; Mo Z
    Aging (Albany NY); 2024 Jan; 16(2):1733-1749. PubMed ID: 38244582
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients.
    Xie LL; Huang YB; Dong KR; Yang SB; Shen C; Ma YY
    BMC Pediatr; 2024 Jan; 24(1):8. PubMed ID: 38172842
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
    Sacco M; Ribaldone DG; Saracco GM
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
    Yin L; Yin AH; Pu CC
    BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Comparison of clinical outcome between laparoscopic and open hepatectomy of high difficulty score for hepatocellular carcinoma: a propensity score analysis.
    Ng KKC; Cheng KC; Kung JWC; Ho KM; Lok HT; Fung AKY; Chong CCN; Cheung SYS; Lee KF; Wong J; Lai PBS
    Surg Endosc; 2024 Feb; 38(2):857-871. PubMed ID: 38082015
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Comparison of Microwave and Radiofrequency Ablation for the Treatment of Small- and Medium-Sized Hepatocellular Carcinomas in a Prospective Randomized Trial.
    Vogl TJ; Martin SS; Gruber-Rouh T; Booz C; Koch V; Nour-Eldin NA; Hussainy Said MN
    Rofo; 2024 May; 196(5):482-490. PubMed ID: 38065541
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability.
    Amin MN; El-Far YM; El-Mowafy M; Elgaml A
    Clin Epigenetics; 2023 Nov; 15(1):180. PubMed ID: 37941056
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. 10 years, 100 robotic major hepatectomies: a single-center experience.
    McCarron F; Cochran A; Ricker A; Mantha R; Driedger M; Beckman M; Vrochides D; Martinie J
    Surg Endosc; 2024 Feb; 38(2):902-907. PubMed ID: 37845533
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Comparison of Baseline
    Wu M; Wang Y; Yang Q; Wang X; Yang X; Xing H; Sang X; Li X; Zhao H; Huo L
    J Nucl Med; 2023 Oct; 64(10):1532-1539. PubMed ID: 37500263
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Transarterial chemoembolization
    Yang B; Yuan M; Yang T; Liao Z; Wu H
    Oncol Res; 2022; 30(1):23-33. PubMed ID: 37304009
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real-world experience.
    Lin PT; Hung MH; Shao SC; Chen HY; Chan YY; Chang KC; Lin SM; Ou HT
    Cancer Med; 2023 Jul; 12(14):14902-14911. PubMed ID: 37278402
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
    Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
    BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. ScRNA-seq revealed targeting regulator of G protein signaling 1 to mediate regulatory T cells in Hepatocellular carcinoma.
    Zou L; Liu K; Shi Y; Li G; Li H; Zhao C
    Cancer Biomark; 2023; 36(4):299-311. PubMed ID: 36938729
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Sero-epidemiological characteristics of the hepatitis D virus infection among hepatitis B virus infected-patients at a single center in Xinjiang region].
    Zheng RJ; Talafu T; Deng ZR; Han D; Pan KJ; Lu XB
    Zhonghua Gan Zang Bing Za Zhi; 2022 Oct; 30(10):1044-1049. PubMed ID: 36727249
    [No Abstract]    [Full Text] [Related]  

  • 18. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
    J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prediction of Protumorigenic Effects after Image-Guided Radiofrequency Ablation of Hepatocellular Carcinoma Using Biomarkers.
    Stechele M; Wildgruber M; Markezana A; Kästle S; Öcal E; Kimm MA; Alunni-Fabbroni M; Paldor M; Haixing L; Salvermoser L; Pech M; Powerski M; Galun E; Ricke J; Goldberg SN
    J Vasc Interv Radiol; 2023 Sep; 34(9):1528-1537.e1. PubMed ID: 36442741
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 24.